Addex Therapeutics Ltd - ADR Stock

$8.02

5.94% day before yesterday

Nasdaq, May 30, 10:00 pm CET

ISIN

US00654J1079

Symbol

ADXN

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

Addex Therapeutics Ltd - ADR Stock price

$8.02

-137.58 94.49% 5Y

Nasdaq, Closing price Fri, May 30 2025

+0.45 5.94%

ISIN

US00654J1079

Symbol

ADXN

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Key metrics

Market capitalization	$12.69m
Enterprise Value	$8.68m
P/E (TTM) P/E ratio	89.11
EV/FCF (TTM) EV/FCF	negative
EV/Sales (TTM) EV/Sales	8.86
P/S ratio (TTM) P/S ratio	12.95
P/B ratio (TTM) P/B ratio	67.00
Revenue growth (TTM) Revenue growth	-51.00%
Revenue (TTM) Revenue	$980.00k
EBIT (operating result TTM) EBIT	$-2.87m
Free Cash Flow (TTM) Free Cash Flow	$-6.54m
Cash position	$4.07m
EPS (TTM) EPS	$0.09
P/E forward	negative
P/S forward	7.10
EV/Sales forward	4.86
Short interest	0.30%

As a Free StocksGuide user, you can view scores for all 6,782 stocks worldwide.

Get Started for Free Today

Addex Therapeutics Ltd - ADR Stock Analysis

Unlock Scores for Free

??

2 Analysts have issued a Addex Therapeutics Ltd - ADR forecast:

2x Sell

100%

More details on Analyst Estimates Including Price Targets

2 Analysts have issued a Addex Therapeutics Ltd - ADR forecast:

Sell

100%

Analyst Estimates with Stock Price Targets

Financial data from Addex Therapeutics Ltd - ADR

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Dec '24		+/- %
Revenue	0.98 0.98	51% 51% 100%
- Direct Costs	- -	- -
Gross Profit	- -	- -
- Selling and Administrative Expenses	2.70 2.70	55% 55% 276%
- Research and Development Expense	0.94 0.94	92% 92% 96%
EBITDA	-2.55 -2.55	79% 79% -260%
- Depreciation and Amortization	0.32 0.32	14% 14% 33%
EBIT (Operating Income) EBIT	-2.87 -2.87	77% 77% -293%
Net Profit	9.07 9.07	171% 171% 926%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Addex Therapeutics Ltd - ADR Stock News

Neutral

GlobeNewsWire

●

21 days ago

Addex Partner Indivior Advances GABAB Positive Allosteric Modulator Program Successfully Through IND Enabling Studies

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, May 12, 2025 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today partner Indivior has successfully advanced its GABAB positive allosteric modulator (PAM) program through IND ena...

Neutral

GlobeNewsWire

●

about one month ago

Addex Enters Option Agreement with Sinntaxis for an Exclusive License to Intellectual Property Covering the Use of mGlu5 Inhibitors in Brain Injury Recovery

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 30, 2025 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that it has entered into an option- and collaboration agreement with Sinntaxis AB (www.sinntaxis.com) for an e...

Neutral

Seeking Alpha

●

about one month ago

Addex Therapeutics Ltd (ADXN) Q4 2024 Earnings Call Transcript

Addex Therapeutics Ltd (NASDAQ:ADXN ) Q4 2024 Earnings Conference Call April 25, 2025 10:00 AM ET Company Participants Tim Dyer - Co-Founder, Board Director and Chief Executive Officer Mikhail Kalinichev - Head, Translational Science Conference Call Participants Peter Ehrlich - AikenSalt Raghuram Selvaraju - HC Wainwright & Co Tim Dyer Hello everyone. I would like to thank you all for attending...

More Addex Therapeutics Ltd - ADR News

Company Profile

Addex Therapeutics Ltd. is a biopharmaceutical company, which engages in the development of drugs for human health. It develops novel, orally available, and small molecule allosteric modulators for neurological disorders. The company was founded by Vincent Mutel, Timothy Dyer, and Mark Epping-Jordan in 2002 and is headquartered in Geneva, Switzerland.

Head office	Switzerland
CEO	Tim Dyer
Employees	23
Founded	2002
Website	www.addextherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now